<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03048825</url>
  </required_header>
  <id_info>
    <org_study_id>CLSYN.1702</org_study_id>
    <secondary_id>OASIS-9</secondary_id>
    <nct_id>NCT03048825</nct_id>
  </id_info>
  <brief_title>Colchicine and Spironolactone in Patients With STEMI / SYNERGY Stent Registry</brief_title>
  <acronym>CLEAR-SYNERGY</acronym>
  <official_title>A 2x2 Factorial Randomized Controlled Trial of Colchicine and Spironolactone in Patients With ST-elevation Myocardial Infarction (STEMI) / SYNERGY Stent Registry - CLEAR-SYNERGY (OASIS-9)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CLEAR SYNERGY trial will study the long term effects of treatments following PCI to treat
      ST elevation myocardial infarction. These treatments address both the culprit artery (PCI
      with SYNERGY Stent) as well as the non-culprit arteries (randomization to routine colchicine
      and spironolactone).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, international SYNERGY Stent registry that is embedded within a
      randomized, blinded, double-dummy, 2x2 factorial design trial of colchicine versus placebo
      and spironolactone versus placebo in patients with ST-elevation myocardial infarction who
      have undergone primary percutaneous coronary intervention (PCI).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-dummy masking of colchicine and spironolactone in 2x2 factorial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Major Adverse Cardiac Events (MACE) for SYNERGY Stent (defined as the composite of death, recurrent target vessel MI, stroke, or ischemia driven target vessel revascularization) compared to performance goal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of cardiovascular death, recurrent myocardial infarction, or stroke</measure>
    <time_frame>through study completion, an estimated average of 2 years</time_frame>
    <description>The first occurrence of cardiovascular death, recurrent myocardial infarction, or stroke in the colchicine comparison</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of cardiovascular death or new or worsening heart failure</measure>
    <time_frame>through study completion, an estimated average of 2 years</time_frame>
    <description>The first occurrence of cardiovascular death or new or worsening heart failure in the spironolactone comparison</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Colchicine + Spironolactone +/- SYNERGY Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 0.5 mg tablet + Spironolactone 25 mg tablet.
Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spironolactone +/- SYNERGY Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine-placebo tablet + Spironolactone 25 mg tablet.
Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colchicine +/- SYNERGY Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 0.5 mg tablet + Spironolactone-placebo tablet.
Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo +/- SYNERGY Stent</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Colchicine-placebo tablet + Spironolactone-placebo tablet.
Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Colchicine 0.5 mg twice daily</description>
    <arm_group_label>Colchicine + Spironolactone +/- SYNERGY Stent</arm_group_label>
    <arm_group_label>Colchicine +/- SYNERGY Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>Spironolactone 25 mg once daily</description>
    <arm_group_label>Colchicine + Spironolactone +/- SYNERGY Stent</arm_group_label>
    <arm_group_label>Spironolactone +/- SYNERGY Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SYNERGY Bioabsorbable Polymer Drug-Eluting Stent</intervention_name>
    <description>Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.</description>
    <arm_group_label>Colchicine + Spironolactone +/- SYNERGY Stent</arm_group_label>
    <arm_group_label>Spironolactone +/- SYNERGY Stent</arm_group_label>
    <arm_group_label>Colchicine +/- SYNERGY Stent</arm_group_label>
    <arm_group_label>Placebo +/- SYNERGY Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine-Placebo</intervention_name>
    <description>Matching Colchicine-placebo twice daily</description>
    <arm_group_label>Spironolactone +/- SYNERGY Stent</arm_group_label>
    <arm_group_label>Placebo +/- SYNERGY Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone-Placebo</intervention_name>
    <description>Matching Spironolactone-Placebo once daily</description>
    <arm_group_label>Colchicine +/- SYNERGY Stent</arm_group_label>
    <arm_group_label>Placebo +/- SYNERGY Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with STEMI referred for PCI within 12 hours of symptom onset, and have
             culprit lesion amenable to stenting (after the initial 800 patients received SYNERGY
             stent [SYNERGY Stent phase], patients will be eligible if referred within 24 hours of
             symptom onset)

             (All patients participating in the drug portion are required to be randomized within
             24 hours of index PCI and during initial hospitalization)

          2. Written informed consent

        Exclusion Criteria:

          1. Known allergy or contraindication to everolimus, the SYNERGY stent or any of its
             components

          2. Unable to receive dual antiplatelet therapy

          3. Age ≤18 years

          4. Pregnancy, breastfeeding, or women of childbearing potential who are not using an
             effective method of contraception

          5. Any contraindication or known intolerance to colchicine or spironolactone

          6. Requirement for colchicine or spironolactone for another indication

          7. Creatinine clearance &lt;30 mL/min/1.73 m^2

          8. History of cirrhosis or current severe hepatic disease

          9. Systolic blood pressure &lt;90 mm Hg

         10. Serum Potassium &gt;5.0 meq/L

         11. Current or planned use of HIV protease inhibitors, azole antifungals, or macrolide
             antibiotics

         12. Active diarrhea

         13. Any medical, geographic, or social factor making study participation impractical or
             precluding follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjit S Jolly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Zapallow, MSc</last_name>
    <phone>9055274322</phone>
    <phone_ext>40513</phone_ext>
    <email>clear@phri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brandi Meeks, MSc</last_name>
    <phone>9055274322</phone>
    <email>clear@phri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CLEAR Investigator</last_name>
      <phone>9055274322</phone>
      <email>clear@phri.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

